Veracyte (VCYT) Operating Expenses (2012 - 2026)

Veracyte has reported Operating Expenses for 15 years, with the latest figure at $85.6 million in Q2 2026.

• Operating Expenses for Q2 2026 came in at $85.6 million, down 9.96% year-over-year; the trailing twelve-month figure through Jun 2026 was $297.2 million (down 5.11% YoY), and the FY2025 annual result was $304.8 million, up 8.07% from the prior year.
• Operating Expenses climbed to $85.6 million in Q2 2026, from $78.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $100.3 million in Q4 2023 and troughed at -$35.1 million in Q4 2022.
• A 5-year average of $73.0 million and a median of $77.6 million in 2025 frame the typical range for Operating Expenses.
• The widest annual swing landed in 2022, when Operating Expenses sank 144.1%; it then soared 385.43% in 2023.
• A 5-year view of Operating Expenses shows it stood at -$35.1 million in 2022, then soared by 385.43% to $100.3 million in 2023, then retreated by 25.64% to $74.6 million in 2024, then decreased by 13.14% to $64.8 million in 2025, then surged by 32.1% to $85.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $85.6 million in Q2 2026, $78.5 million in Q1 2026, and $64.8 million in Q4 2025.